Inflammatory bowel diseases patients suffer from significant low levels and barriers to physical activity: The "BE-FIT-IBD" study.
Crohn’s disease
Inflammatory bowel disease
International Physical Activity Questionnaire
Physical activity
Ulcerative colitis
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Nov 2023
07 Nov 2023
Historique:
received:
16
08
2023
revised:
09
10
2023
accepted:
23
10
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
ppublish
Résumé
The place regular physical activity (PA) should occupy in managing patients with inflammatory bowel diseases (IBD) is unclear. To assess PA levels and barriers in a southern Italian IBD population. IBD patients with non-severe disease activity [assessed with partial Mayo score for ulcerative colitis (UC) and Harvey-Bradshaw index for Crohn's disease] were approached to receive an anonymous online questionnaire to assess PA levels using the International Physical Activity Questionnaire (IPAQ) and to assess disease activity as patient-reported outcomes 2 (PRO-2) and finally to assess habits, beliefs and barriers in conducting regular PA. Clinical, anthropometric and demographic data of patients were also collected. PA was expressed as continuous units of resting metabolic rate (Met) in min/wk. Three PA groups were identified: Inactive (< 700 Met min/wk), sufficiently active (700-2500 Met min/wk) and health enhancing PA (HEPA) ( Included patients (219) showed overall PA levels of 834.5 Met min/wk, with a large proportion (94, 42.9%) classified as inactive while only a minority (9, 4.1%) as health-enhancing PA. Patients without dyslipidaemia ( A significant rate of physical inactivity was recorded in this setting. IPAQ showed good feasibility. PA should be an element of discussion in IBD visits assessed quickly with non-invasive questionnaires.
Sections du résumé
BACKGROUND
BACKGROUND
The place regular physical activity (PA) should occupy in managing patients with inflammatory bowel diseases (IBD) is unclear.
AIM
OBJECTIVE
To assess PA levels and barriers in a southern Italian IBD population.
METHODS
METHODS
IBD patients with non-severe disease activity [assessed with partial Mayo score for ulcerative colitis (UC) and Harvey-Bradshaw index for Crohn's disease] were approached to receive an anonymous online questionnaire to assess PA levels using the International Physical Activity Questionnaire (IPAQ) and to assess disease activity as patient-reported outcomes 2 (PRO-2) and finally to assess habits, beliefs and barriers in conducting regular PA. Clinical, anthropometric and demographic data of patients were also collected. PA was expressed as continuous units of resting metabolic rate (Met) in min/wk. Three PA groups were identified: Inactive (< 700 Met min/wk), sufficiently active (700-2500 Met min/wk) and health enhancing PA (HEPA) (
RESULTS
RESULTS
Included patients (219) showed overall PA levels of 834.5 Met min/wk, with a large proportion (94, 42.9%) classified as inactive while only a minority (9, 4.1%) as health-enhancing PA. Patients without dyslipidaemia (
CONCLUSION
CONCLUSIONS
A significant rate of physical inactivity was recorded in this setting. IPAQ showed good feasibility. PA should be an element of discussion in IBD visits assessed quickly with non-invasive questionnaires.
Identifiants
pubmed: 38077160
doi: 10.3748/wjg.v29.i41.5668
pmc: PMC10701332
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5668-5682Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: There are no conflicts of interest to report.
Références
J Hepatol. 2010 Aug;53(2):372-84
pubmed: 20494470
Am J Mens Health. 2017 Jul;11(4):1019-1027
pubmed: 28147893
Int J Mol Sci. 2022 Aug 05;23(15):
pubmed: 35955849
Aliment Pharmacol Ther. 2018 Jan;47(1):6-15
pubmed: 28994131
Inflamm Bowel Dis. 2016 Dec;22(12):2933-2942
pubmed: 27824653
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):
pubmed: 28507196
Inflamm Intest Dis. 2021 May;6(2):61-69
pubmed: 34124177
Best Pract Res Clin Rheumatol. 2020 Apr;34(2):101504
pubmed: 32249021
N Engl J Med. 2020 Dec 31;383(27):2652-2664
pubmed: 33382932
Nutrients. 2019 Jul 19;11(7):
pubmed: 31331009
Ann Gastroenterol. 2021 Nov-Dec;34(6):796-801
pubmed: 34815645
Can J Gastroenterol Hepatol. 2017;2017:6496727
pubmed: 29181373
Inflamm Bowel Dis. 2018 Mar 19;24(4):742-751
pubmed: 29562277
J Clin Invest. 2007 Nov;117(11):3463-74
pubmed: 17932564
Clinics (Sao Paulo). 2005 Feb;60(1):61-70
pubmed: 15838583
Inflamm Bowel Dis. 2019 Nov 14;25(12):1896-1905
pubmed: 30934053
Osteoporos Int. 2017 Jun;28(6):1817-1833
pubmed: 28251287
Biomolecules. 2019 Jun 07;9(6):
pubmed: 31181700
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Aliment Pharmacol Ther. 2015 Nov;42(10):1200-10
pubmed: 26388424
Clin Ter. 2022 Nov-Dec;173(6):546-550
pubmed: 36373453
Lancet Gastroenterol Hepatol. 2022 Jul;7(7):666-678
pubmed: 35487235
Adv Ther. 2022 Dec;39(12):5327-5350
pubmed: 36205907
BMC Med Res Methodol. 2018 Dec 22;18(1):176
pubmed: 30577770
Am J Gastroenterol. 1999 Mar;94(3):697-703
pubmed: 10086654
Aliment Pharmacol Ther. 2015 Jan;41(1):77-86
pubmed: 25348809
Scand J Public Health. 2006;34(2):209-16
pubmed: 16581714
BMJ. 2013 Nov 14;347:f6633
pubmed: 24231178
Int J Environ Res Public Health. 2023 Jan 18;20(3):
pubmed: 36767104
Medicine (Baltimore). 2021 Jul 9;100(27):e26290
pubmed: 34232167
Curr Opin Clin Nutr Metab Care. 2022 May 1;25(3):159-166
pubmed: 35238803
Expert Rev Gastroenterol Hepatol. 2023 Jan;17(1):99-108
pubmed: 36537197
Int J Sports Med. 1996 Apr;17(3):205-12
pubmed: 8739575
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):
pubmed: 28432116
Sport Sci Health. 2021;17(2):459-464
pubmed: 33688376
Eur J Appl Physiol. 2018 Apr;118(4):829-836
pubmed: 29411129
Inflamm Bowel Dis. 2019 Jan 1;25(1):67-73
pubmed: 29889230
Autoimmun Rev. 2018 Jan;17(1):53-72
pubmed: 29108826
Clin J Sport Med. 2007 Sep;17(5):384-8
pubmed: 17873551
Intest Res. 2022 Jan;20(1):43-52
pubmed: 33472342
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174